NASDAQ · ABIO
ARCA biopharma, Inc.
Healthcare · Biotechnology
$28.80
Up+$26.30 (+1052.00%)
Updated Sep 16, 2026, 7:19 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 34.82M
- P/E ratio
- -13.88
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 290.85K
- Avg. volume
- 12.98K
Price performance
ABIO price history
1M range · 0 trading sessions · Daily adjusted prices
ABIO does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest ABIO news
The latest Smart Investors Daily articles mentioning ABIO.
Stock researchCompany · Overview
ABIO research
Overview
Company profile and research snapshot.
Company profile
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.
